Parallel Advisors LLC Buys 42,667 Shares of Pfizer Inc. $PFE

Parallel Advisors LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 49.3% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 129,199 shares of the biopharmaceutical company’s stock after buying an additional 42,667 shares during the period. Parallel Advisors LLC’s holdings in Pfizer were worth $3,628,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Horizon Financial Services LLC increased its position in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer in the 4th quarter worth approximately $28,000. HFM Investment Advisors LLC boosted its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer faces expanded international patent lawsuits over its COVID-19 vaccine, with Arbutus Biopharma and Genevant Sciences seeking damages and possible injunctions. That raises legal and operational uncertainty for the company. Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
• Negative Sentiment: Pfizer was noted as falling more than the broader market in the latest session, reinforcing near-term weakness in the stock. Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
• Negative Sentiment: Erste Group Bank lowered earnings estimates for Pfizer, which can signal softer expectations for future profitability. Erste Group Bank Decreases Earnings Estimates for Pfizer
• Neutral Sentiment: Pfizer has been drawing heavy user interest on Zacks, but the coverage is largely a stock-screening/discussion piece rather than a new company-specific catalyst. Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
• Neutral Sentiment: Separate articles highlighted Pfizer as a possible contender in the $100 billion weight-loss market and as a cheap income stock, which supports the bullish long-term narrative but does not change near-term fundamentals on its own. Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

Pfizer Trading Down 1.2%

PFE opened at $24.75 on Tuesday. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a market cap of $141.04 billion, a P/E ratio of 18.89 and a beta of 0.35. The company has a fifty day moving average price of $25.19 and a two-hundred day moving average price of $26.18.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. BMO Capital Markets dropped their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. JPMorgan Chase & Co. lowered their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. UBS Group reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research note on Tuesday, June 9th. Finally, Wolfe Research reiterated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $28.50.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.